Roche says Trump's drug price order threatens its $50 billion US investment plans

LONDON (Reuters) -U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion investment in the United States, the company said on Wednesday. Trump's order, signed Monday, directs drugmakers to lower prices of brand-name medicines to align with those in other wealthy nations. "Should the proposed EO (Executive Order) go into effect, Roche's ability to fund the significant investments previously announced in the U.S. will be in question," the company said in a statement.